Prime Medicine Inc (NASDAQ: PRME) kicked off on Tuesday, down -0.75% from the previous trading day, before settling in for the closing price of $1.33. Over the past 52 weeks, PRME has traded in a range of $1.12-$8.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. While this was happening, its average annual earnings per share was recorded 27.26%. With a float of $51.92 million, this company’s outstanding shares have now reached $131.16 million.
Let’s look at the performance matrix of the company that is accounted for 214 employees. In terms of profitability, gross margin is 98.55%, operating margin of -496.77%, and the pretax margin is -480.61%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 31.22%.
Prime Medicine Inc (PRME) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.59% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 5.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 58.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 1.77 million, a positive change from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 27.82%. Additionally, its Average True Range was 0.20.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 8.28%, which indicates a significant decrease from 20.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.60% in the past 14 days, which was higher than the 93.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1203, while its 200-day Moving Average is $3.4735. Nevertheless, the first resistance level for the watch stands at $1.3850 in the near term. At $1.4500, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5000. If the price goes on to break the first support level at $1.2700, it is likely to go to the next support level at $1.2200. The third support level lies at $1.1550 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 173.13 million has total of 131,161K Shares Outstanding. Its annual sales at the moment are 2,980 K in contrast with the sum of -195,880 K annual income. Company’s last quarter sales were recorded 2,180 K and last quarter income was -42,280 K.
